[go: up one dir, main page]

WO2001085165A3 - Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems - Google Patents

Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems Download PDF

Info

Publication number
WO2001085165A3
WO2001085165A3 PCT/EP2001/005359 EP0105359W WO0185165A3 WO 2001085165 A3 WO2001085165 A3 WO 2001085165A3 EP 0105359 W EP0105359 W EP 0105359W WO 0185165 A3 WO0185165 A3 WO 0185165A3
Authority
WO
WIPO (PCT)
Prior art keywords
donors
nervous system
central nervous
combination
lipoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/005359
Other languages
English (en)
French (fr)
Other versions
WO2001085165A2 (de
Inventor
Wolfgang Haehnlein
Klaus Kraemer
Oliver Hasselwander
Walter E Mueller
Guenther P Eckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to AU67424/01A priority Critical patent/AU6742401A/en
Priority to IL15268801A priority patent/IL152688A0/xx
Priority to CA002408666A priority patent/CA2408666A1/en
Priority to EP01945113A priority patent/EP1289521A2/de
Priority to JP2001581819A priority patent/JP2003532674A/ja
Publication of WO2001085165A2 publication Critical patent/WO2001085165A2/de
Publication of WO2001085165A3 publication Critical patent/WO2001085165A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Liponsäure und C1-Donoren, insbesondere S-Adenosylmethionin und/oder 5-Methyltetrahydrofolat, zur Behandlung von Störungen des zentralen Nervensystems, Mittel mit einer entsprechenden Wirkstoffkombination sowie Mittel in Form von Handelspackungen mit entsprechenden Kombinationspräparaten oder Monopräparaten zur kombinierten Anwendung.
PCT/EP2001/005359 2000-05-10 2001-05-10 Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems Ceased WO2001085165A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU67424/01A AU6742401A (en) 2000-05-10 2001-05-10 Combination of lipoic acid and C1 donors for the treatment of disorders of the central nervous system
IL15268801A IL152688A0 (en) 2000-05-10 2001-05-10 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
CA002408666A CA2408666A1 (en) 2000-05-10 2001-05-10 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
EP01945113A EP1289521A2 (de) 2000-05-10 2001-05-10 Kombination von liponsäure und c 1-donoren zur behandlung von störungen des zentralen nervensystems
JP2001581819A JP2003532674A (ja) 2000-05-10 2001-05-10 中枢神経系障害を治療するためのリポ酸とｃ１供与体の組合せ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10022856A DE10022856A1 (de) 2000-05-10 2000-05-10 Therapeutische Kombination von Liponsäure und C1-Donoren zur Behandlung von Störungen des Zentralen Nervensystems
DE10022856.9 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001085165A2 WO2001085165A2 (de) 2001-11-15
WO2001085165A3 true WO2001085165A3 (de) 2002-05-02

Family

ID=7641502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005359 Ceased WO2001085165A2 (de) 2000-05-10 2001-05-10 Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems

Country Status (9)

Country Link
US (1) US20030148991A1 (de)
EP (1) EP1289521A2 (de)
JP (1) JP2003532674A (de)
AU (1) AU6742401A (de)
CA (1) CA2408666A1 (de)
DE (1) DE10022856A1 (de)
IL (1) IL152688A0 (de)
WO (1) WO2001085165A2 (de)
ZA (1) ZA200209940B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
DE10255242A1 (de) 2002-11-26 2004-06-03 Basf Ag Verfahren zur Reinigung von Liponsäure
ITMI20030831A1 (it) * 2003-04-22 2004-10-23 Laboratorio Chimico Int Spa Sale basico dell'acido tiottico con la l-carnitina.
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US20070082949A1 (en) * 2003-11-14 2007-04-12 Hiroaki Ootani Agent for preventing and treating language disorders
EP1645276A1 (de) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Behandlung von neurodegenerativen Erkrankungen
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
AU2011215669B2 (en) * 2010-02-12 2015-06-04 HedoniaUSA, Inc. Compositions and methods for treating depression
AU2013299656C1 (en) * 2012-08-07 2017-06-22 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
AU2017397463B2 (en) * 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (de) * 1965-06-09 1966-11-28
US4057686A (en) * 1974-07-12 1977-11-08 Bioresearch Limited Sulphonic acid salts of S-adenosilmethionine
EP0388827A1 (de) * 1989-03-22 1990-09-26 BIORESEARCH S.p.A. Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
DE4343592A1 (de) * 1993-12-21 1995-06-22 Asta Medica Ag Verwendung von R-(+)alpha-Liponsäure, R-(-)-Dihydroliponsäure und deren Metabolite in Form der freien Säure oder als Salze oder Ester oder Amide zur Herstellung von Arzneimitteln zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystem

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (de) * 1965-06-09 1966-11-28
US4057686A (en) * 1974-07-12 1977-11-08 Bioresearch Limited Sulphonic acid salts of S-adenosilmethionine
EP0388827A1 (de) * 1989-03-22 1990-09-26 BIORESEARCH S.p.A. Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
DE4343592A1 (de) * 1993-12-21 1995-06-22 Asta Medica Ag Verwendung von R-(+)alpha-Liponsäure, R-(-)-Dihydroliponsäure und deren Metabolite in Form der freien Säure oder als Salze oder Ester oder Amide zur Herstellung von Arzneimitteln zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystem

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PASSERI M ET AL: "ORAL 5 METHYLTETRAHYDROFOLATE MTHF IN DEPRESSION ASSOCIATED WITH SENILE ORGANIC MENTAL DISORDERS OMDS A DOUBLE-BLIND MULTICENTER STUDY VS TRAZODONE TRZ.", 25TH MEETING OF THE EUROPEAN SOCIETY FOR CLINICAL INVESTIGATION, PISA, ITALY, APRIL 3-6, 1991. EUR J CLIN INVEST. (1991) 21 (2 PART 2), 24., XP001029044 *
STOLL, S. (1) ET AL: "The potent free radical scavenger alpha - lipoic acid improves cognition in rodents.", ZS.-NAGY, I. [EDITOR];HARMAN, D. [EDITOR]; KITANI, K. [EDITOR]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1994) VOL. 717, PP. 122-128. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES; PHARMACOLOGY OF AGING PROCESSES: METHODS OF ASSESSMENT AND POTENTIAL, XP001029748 *

Also Published As

Publication number Publication date
AU6742401A (en) 2001-11-20
EP1289521A2 (de) 2003-03-12
IL152688A0 (en) 2003-06-24
WO2001085165A2 (de) 2001-11-15
JP2003532674A (ja) 2003-11-05
US20030148991A1 (en) 2003-08-07
DE10022856A1 (de) 2001-11-15
CA2408666A1 (en) 2002-11-08
ZA200209940B (en) 2003-12-09

Similar Documents

Publication Publication Date Title
WO2001095899A8 (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
WO2000035919A3 (en) Quinoline derivatives
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
WO2003080582A3 (de) Fredericamycin-derivate
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
WO2001051051A3 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
EP0922461A4 (de) Heilmittel gegen hyperphosphatanämie
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
WO2001085165A3 (de) Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
MXPA03011825A (es) Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos.
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2001043705A3 (en) Compositions containing a retinoid and a stilbene for skin care
HK1045987A1 (zh) 3-氨基-2-苄基-1-苯基-丙烷衍生物
ZA963744B (en) Topical aciclovir preparation
PT862433E (pt) Composicao farmaceutica espumante topica para o tratamento de dermatoses induzidas por pityrosporum oval
AU2001235706A1 (en) Cosmetic or medicinal composition containing sesquiterpene lactone or the like for treating hair-growth related disorders, and preparation method
WO2001000189A3 (de) Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 152688

Country of ref document: IL

Ref document number: 2001945113

Country of ref document: EP

Ref document number: 10275579

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2408666

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002/09940

Country of ref document: ZA

Ref document number: 200209940

Country of ref document: ZA

Ref document number: 67424/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001945113

Country of ref document: EP